HD-OPM Archive
Topics › Supplements & vitamins

Small RCT: vitamin D raised pathological complete response to 43% vs 24% in breast cancer

Louis Nervegna · Jul 25, 2026 · ♥ 3 reactions · 0 comments · original Facebook post
Supplements & vitaminsCancer
AI summary & key facts

In an 80-woman Brazilian trial, women aged 45+ starting neoadjuvant chemotherapy received 2,000 IU vitamin D daily or placebo for six months. Complete response occurred in 43% vs 24% among 75 who reached surgery. The commentary notes the benefit tracked correction of deficiency and that pathologic complete response is not a validated surrogate endpoint.

A remarkable small randomized trial of vitamin D in breast cancer.

Link to journal paper:

Paper · Nutr Cancer · 2025Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial.This study aimed to evaluate the effect of vitamin D (VD) supplementation on the pathological complete response (pCR) rate in women with breast cancer (BC) undergoing neoadjuvant chemotherapy (NCT). A randomized clinical trial was conducted with 80 women aged ≥45years with BC who were eligible for NCT. Women were randomized into two groups: VD group, daily supplementation with 2,000IU of cholecalciferol (n = 40) or…pubmed.ncbi.nlm.nih.gov

#vitamindHD #breastcancerHD

Research cited

Sometimes chemotherapy clears a tumour so completely that the surgeon finds nothing left to remove.

That outcome has a name, pathological complete response, and it is not a technicality. In a pooled analysis of 12 international trials and 11,955 patients, funded by the FDA, women who achieved it had substantially better event-free and overall survival, with the strongest association in triple-negative and HER2-positive disease.

So a trial that moves that number gets attention. In Brazil, 80 women aged 45 and over starting chemotherapy before surgery were randomized to 2,000 IU of vitamin D daily or placebo for six months. Among the 75 who completed treatment and went to surgery, complete response occurred in 43 percent on vitamin D against 24 percent on placebo.

Both groups had hypovitaminosis D at enrollment, averaging 19.6 and 21 ng/mL. The supplemented group finished at 28, still under the 30 mark most labs treat as sufficient. Placebo finished at 20.2, essentially unchanged. The trial's own regression found the predictor of complete response was crossing 20 ng/mL, which is the deficiency line, not reaching a high level. This corrected a shortfall. It did not test whether extra vitamin D helps someone already replete.

The larger caution comes from that same FDA analysis. It established that patients who achieve complete response do better, but it could not validate the measure as a surrogate endpoint. An intervention that raises the complete response rate has not thereby been shown to improve survival. Those are separate claims, and this trial only supports the first.

What is left is a genuine randomized result, in 75 women, at a single centre, on a surgical finding rather than a survival outcome, in a population that was deficient to begin with. That is worth following.

Omodei et al., Nutr Cancer 2025 · PMID 40098326
Cortazar et al., Lancet 2014 · PMID 24529560

No photo description available.
← newer: Summary of Dudley Lamming's isoleucine restriction research older: Cleveland Clinic links gut-bacteria byproduct TMAO to atrial →